Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Shares Issued (2020 - 2025)

Maxcyte (MXCT) has disclosed Shares Issued for 5 consecutive years, with $14000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued fell 93.86% to $14000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$503000.0, a 131.38% decrease, with the full-year FY2024 number at $459000.0, down 75.51% from a year prior.
  • Shares Issued was $14000.0 for Q3 2025 at Maxcyte, down from $20000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $49.8 million in Q2 2021 to a low of -$51.8 million in Q4 2021.
  • A 5-year average of $313222.2 and a median of $354250.0 in 2022 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 516.22% in 2024; the steepest drop was 510.71% in 2024.
  • Maxcyte's Shares Issued stood at -$51.8 million in 2021, then surged by 102.37% to $1.2 million in 2022, then crashed by 81.72% to $224000.0 in 2023, then crashed by 510.71% to -$920000.0 in 2024, then surged by 101.52% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Issued are $14000.0 (Q3 2025), $20000.0 (Q2 2025), and $383000.0 (Q1 2025).